Home / Industry / Medical Devices / Uterine Cancer Diagnostic Testing Market

Uterine Cancer Diagnostic Testing Market

Global Uterine Cancer Diagnostic Testing Industry Analysis, Size, Share, Growth, Trends, and Forecast 2024-2031- (By Type Coverage, By End User Coverage, By Geographic Coverage and By Company)

Published Date: Aug 2024 | Format: | No. of Pages: 153

Industry: Medical Devices | Author Name: Harshad

Request Customisation / Information

  
$4,995.00
Buy now
Report Description Research Methodology

FAQ : Uterine Cancer Diagnostic Testing Market

The market is predicted to rise from US$3.23 Bn in 2024 to US$6.56 Bn by 2031.

The rising obesity, diabetes, Cowden syndrome, tamoxifen consumption, a sedentary lifestyle, and technological advancements in this field are propelling industry growth.

Key companies profiled in the market include Ariad Pharmaceuticals, Abbott Laboratories, Becton, Dickinson & Co., GlaxoSmithKline Plc, Merck & Co., Inc., Novartis AG, Sanofi, Siemens Healthcare Inc., Roche Ltd., and MiMARK Diagnostics.

Challenges like limited awareness and screening programs and high diagnostic test costs are restraining market expansion.

The shift towards non-invasive and blood-based diagnostic tests and the integration of precision medicine and digital health solutions are significant factors creating opportunities in the market.
Fairfield Quality assured
Fairfield Confidentiality assured
Fairfield Custom research services